Tuttle RM. (2011)
-
- いいね！0
Seiichi Ushikubo
@sushikubo
Clinical Presentation and Clinical Outcomes in Chernobyl-related Paediatric Thyroid Cancers. Tuttle R.M. et.al. 2011. http://t.co/bpjsaRoF
2012-09-17 00:29:50チェルノブイリの悲劇から25年が経とうとしているが、私たちに仕事は終わっていない。
最も影響を受けた3カ国の仲間と患者は、進んだ診断方法と治療を行い、すばらしい予後を達成し、さらなる悲劇を避けることだろう。
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. Clinical Oncology 23 (2011) "It is only by ensuring that ..."
2012-09-17 00:36:10
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. 2011. "... that our colleagues and their patients in these three most affected countries ..."
2012-09-17 00:41:06
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. 2011 "... have access to modern disease detection tools and treatments ..."
2012-09-17 00:42:37
Seiichi Ushikubo
@sushikubo
myen Tuttle R.M. 2011 "... that we can reasonably expect to achieve excellent clinical outcomes and avoid a future tragedy ..."
2012-09-17 00:44:13
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. 2011 "... in which higher than necessary rates of morbidity and mortality are associated with recurrences ..."
2012-09-17 00:47:14
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. 2011 "... that were not detected and treated in a timely manner."
2012-09-17 00:47:50
Seiichi Ushikubo
@sushikubo
Tuttle (2011) Talbe 1. Initial presenting features and primary clinical outcomes http://t.co/60leaA2j
2013-02-14 18:43:30
Seiichi Ushikubo
@sushikubo
Tuttle R.M. (2011) Fig. 1 チェルノブイリ事故後の甲状腺癌患者の初発時臨床像と経過の集計 N 2149例, リンパ節転移(N1) 60%, 遠隔転移(M1) 8%, 死亡 0.69%, 再発 17% http://t.co/bpjsaRoF
2012-09-18 00:10:09
Seiichi Ushikubo
@sushikubo
Tuttle RM. (2011) Table 3 paediatric, non-radiation-related differentiated thyroid cancers http://t.co/fWDRa73T
2013-02-14 18:49:32
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275. Table 4. Summary data ... http://t.co/bpjsaRoF http://t.co/Ji0tzKZP
2012-09-17 00:54:10
拡大
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(1) http://t.co/RezQLWFF N 133, N1 60%, M1 5% http://t.co/bpjsaRoF
2012-09-17 23:40:31
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(5) http://t.co/9ALHrZYS N 472, N1 65%, M1 8% http://t.co/bpjsaRoF
2012-09-17 23:44:13
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(6) http://t.co/ir3K66gC N 232, N1 62%, M1 17% http://t.co/bpjsaRoF
2012-09-17 23:50:58
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(7) http://t.co/iNSY7Llq N 330, N1 57%, M1 15% http://t.co/bpjsaRoF
2012-09-17 23:53:16
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(8) http://t.co/i1J744hc N 22, N1 55%, M1 0%, http://t.co/bpjsaRoF
2012-09-17 23:55:02
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(9) http://t.co/MN48O4LK N 48, N1 60%, M1 8% http://t.co/bpjsaRoF
2012-09-17 23:56:38
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(10) http://t.co/GWYBhyyt N 740, N1 69%, M1 10% http://t.co/MktAA0Pn
2012-09-17 23:58:58
Seiichi Ushikubo
@sushikubo
@myen Tuttle R.M. et.al. Clinical Oncology 23 (2011) 268-275 Fig 1 文献(11) http://t.co/wVWBlJBr N 172, N1 55%, M1 4% http://t.co/bpjsaRoF
2012-09-18 00:01:05